Inactivating GNAI2 alterations occur in about 6% of colorectal cancer patients, which is about the frequency of oncogenic β-catenin (5%) or conductin (7%) mutations but far below the loss of APC (77%), the major tumor suppressor of the Wnt pathway2. This evidence concerns the gene AXIN2 and neoplasm.